Proof of Usefulness Report

Brii Biosciences

Analysis completed on 2/3/2026

+568
Proof of Usefulness Score
Industry Mainstay

Brii Biosciences is a legitimate, publicly traded biotechnology company (HKEX: 2137) with significant real-world utility in infectious disease treatment. However, the project submission appears to be automated or low-effort, evidenced by the invalid email format, the false claim that 'most people have used my product', and the confusion of market cap with revenue. While the underlying entity is high-value and verified (Market Cap ~$140M USD), the score is penalized heavily for the inaccurate and lazy submission details.

Ready to Compete for $150k+ in Prizes?

Move this data into a HackerNoon blog draft to become eligible for your share of $150k+ in cash and software prizes

View All Reports

Score Breakdown

Real World Utility+225.0
Audience Reach Impact+70.0
Technical Innovation+127.5
Evidence Of Traction+112.5
Market Timing Relevance+80.0
Functional Completeness+2.5
Subtotal+617.5
Usefulness Multiplierx0.92
Final Score+568

Project Details

Project URL
http://www.briibio.com
Description
Brii Biosciences is a biotechnology company developing therapies to address major public health challenges where patients experience high unmet medical needs, limited choice and significant social stigmas. With a focus on infectious diseases and central nervous system diseases, we have built a robust pipeline of potential treatment options based on patient insights and experiences, and are advancing these differentiated investigational therapies to address patient choice. Led by a visionary and experienced leadership team, Brii Bio has deep scientific expertise and a proven ability to progress therapeutic assets from discovery to commercial approval on a consolidated timeline. Established in 2018, Brii Bio now has operations in key biotech hubs, including Raleigh-Durham, the San Francisco Bay Area, Beijing and Shanghai. On July 13, 2021, the Company was officially listed on the Hong Kong Stock Exchange under the stock code 2137.HK.

Algorithm Insights

Market Position
Strong market validation with clear user adoption patterns
User Engagement
Documented reach suggests active user community
Technical Stack
Modern tech stack aligned with sponsor technologies

Recommendations to Increase Usefulness Score

Document User Growth

Provide specific metrics on user acquisition and retention rates

Showcase Revenue Model

Detail sustainable monetization strategy and current revenue streams

Expand Evidence Base

Include testimonials, case studies, and third-party validation

Technical Roadmap

Share development milestones and feature completion timeline